Jena

• Efficacy and safety of Dalbavancin in the treatment of infective Endocarditis caused by gram-positive cocci Pending
  2026-526149-91-00 5 Infectious endocarditis caused by Gram-positive cocci (staphylococci,
• Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukem … Recruiting
  2025-521390-14-00 4 2026-06-22 Acute Myeloid Leukemia
• A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Recruiting
  2025-523576-23-00 5 2026-06-12 Unresectable Stage III non-small cell lung cancer without progression
• A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Recruiting
  2025-524316-11-00 5 2026-06-11 Primary Progressive Multiple Sclerosis (PPMS)
• Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Recruiting
  2025-521590-13-00 5 2026-05-28 Moderately to Severely Active Crohn’s Disease
• Study of GVV858 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and other advanced solid … Recruiting
  2025-521911-38-00 7 2026-05-26 Advanced HR+/HER- breast cancer
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 5 2026-05-11 Atherosclerotic cardiovascular disease (ASCVD)
• A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-021) Recruiting
  2023-508047-40-00 5 2026-04-30 Ovarian cancer
• STAMPEDE2: A randomised controlled platform trial testing treatments in metastatic hormone sensitive prostate cancer Recruiting
  2025-522145-21-00 5 2026-04-13 Metastatic hormone sensitive prostate cancer
• Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting
  2025-522279-27-00 5 2026-04-02 Newly Diagnosed AML with an NPM1 mutation
• A study to investigate safety, tolerability, pharmacokinetics, and pharmacodynamics of surovatamig in adult participants with rheumatoid art … Recruiting
  2025-522273-10-00 3 2026-02-24 Rheumatoid Arthritis
• A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific … Recruiting
  2025-522767-15-00 5 2026-01-27 Acute Myeloid Leukemia
• A clinical study of sacituzumab tirumotecan for cervical cancer (MK-2870-036) Recruiting
  2025-521514-26-00 5 2026-01-26 Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer W
• A Multi-Stage Study to Test a New Drug in Healthy Adult Volunteers, Then in Adults with Ulcerative Colitis Recruiting
  2025-522702-21-00 4 2026-01-26 Ulcerative Colitis is a type of inflammatory bowel disease, a chronic
• Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL. Recruiting
  2025-522052-13-00 10 2025-12-24 Framework for Optimizing, Refining, and Unifying Management of HSCT in
• CLEOPATTRA: A research study to look at the effects of treatment with a medicine called coramitug (NNC6019-0001) in people with heart failur … Recruiting
  2024-518899-31-00 5 2025-12-19 Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy
• STOP-PKD: SGLT2-inhibition to improve Prognosis in Polycystic Kidney Disease Recruiting
  2025-521276-59-00 5 2025-12-16 Autosomal dominant polycystic kidney disease (ADPKD)
• Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC. Recruiting
  2024-516906-47-00 10 2025-11-28 Locally Advanced or Metastatic Urothelial Carcinoma
• An Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting
  2024-518006-40-00 5 2025-11-13 Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD)
• A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis Recruiting
  2025-520721-21-00 4 2025-10-20 Rheumatoid Arthritis
• A phase Ib, open-label, ascending dose study to assess safety, tolerability and pharmacokinetics of PIT565 in participants with rheumatoid a … Recruiting
  2024-520196-27-00 3 2025-10-01 Rheumatoid Arthritis
• Open-label Study of ELA026 in Participants with sHLH (short title) Recruiting
  2025-520624-25-00 10 2025-09-19 Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
• The AIRTIVITY TM Study: A study to find out whether BI 1291583 helps people with bronchiectasis Recruiting
  2024-518589-29-00 5 2025-08-21 Bronchiectasis
• Multicenter, Open-Label, Randomized Study of Nipocalimab or IVIG in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (F … Recruiting
  2023-509434-19-00 5 2025-02-10 Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Showing 25–48 of 328 trials